CRLNYSEServices-Commercial Physical & Biological ResearchFiscal year ends December 27
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Aug 5, 2026
$300.02−0.13 (-0.04%)
Close on Oct 19, 2026
- Market cap
- $14.41B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
–
Operating margin
0.6%−14.2 pts over 5 years
Net margin
-3.6%−16.1 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -0.9% | +0.3% | +6.5% | +11.4% | |
| Operating income | -88.9% | -66.2% | -43.4% | -19.0% | |
| Free cash flow | +3.4% | +20.7% | +6.4% | +7.8% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 19.7% | 19.4% | -4.4% | |
| Return on assets | 6.5% | 7.2% | -2.0% | |
| Current ratio | 1.53 | 1.43 | 1.29 | |
| Debt to equity | 1.45 | 0.93 | 0.68 | |
| Net debt to EBITDA | 3.00× | 2.61× | 4.49× | |
| Interest coverage | 8.6× | 5.0× | 0.2× | |
| Inventory turnover | 2.9× | – | – | |
| Capex to revenue | 3.3% | 5.7% | 5.5% | |
| Diluted shares | 48M | 51M | 50M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Charles River Laboratories International generated $3.54B from operations and spent $1.91B on capital expenditure, dividends and share buybacks. 69% of that went back into the business.
Generated
$3.54B
Used
$1.91B
Capital expenditure$1.32B69%Dividends$00%Share buybacks$583.36M31%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-3.6%
×Asset turnover0.55×
×Equity multiplier2.21×
=Return on equity, FY2025-4.4%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -3.6% | 0.55× | 2.21× | -4.4% |
| FY2024 | 0.5% | 0.52× | 2.23× | 0.6% |
| FY2023 | 11.5% | 0.52× | 2.40× | 14.4% |
| FY2022 | 12.2% | 0.54× | 2.65× | 17.6% |
| FY2021 | 11.0% | 0.57× | 2.69× | 16.8% |
| FY2020 | 12.5% | 0.57× | 2.72× | 19.4% |
| FY2019 | 9.6% | 0.61× | 2.90× | 17.1% |
| FY2018 | 10.0% | 0.67× | 2.87× | 19.2% |
| FY2017 | 6.6% | 0.66× | 3.00× | 13.1% |
| FY2016 | 9.2% | 0.70× | 3.05× | 19.7% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$144.34M
- Cash generatingOperating cash flow above zero$737.65M
- Return on assets improvedROA up on the prior year0.3% → -1.9%
- Earnings backed by cashOperating cash flow above net income$737.65M vs -$144.34M
- Less leverageLong-term debt to assets fell29.8% → 29.9%
- Better liquidityCurrent ratio rose1.41 → 1.29
- No dilutionShare count did not rise52M → 50M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.49 → 0.53